Thalidomide continues to be a highly active agent in multiple myeloma, demonstrating power that outclasses standard chemotherapy. Although the drug needs to undergo further clinical trials, this approach could advance treatment of multiple myeloma and give patients a new treatment option.
Go to Previous Page
Go to Next Page